Liquidia Co. (NASDAQ:LQDA) Given Consensus Rating of "Moderate Buy" by Analysts

Liquidia Co. (NASDAQ:LQDA - Get Free Report) has received an average rating of "Moderate Buy" from the ten brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $24.00.

Several analysts recently commented on LQDA shares. Scotiabank started coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price objective for the company. BTIG Research lowered their price target on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a report on Monday, August 19th. HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Bank of America reduced their price target on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Tuesday, August 20th. Finally, Lifesci Capital assumed coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 price target on the stock.

Insider Buying and Selling

In other news, CEO Roger Jeffs sold 8,053 shares of the company's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the transaction, the chief executive officer now owns 812,193 shares in the company, valued at $9,023,464.23. This represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Caligan Partners Lp bought 150,000 shares of the company's stock in a transaction dated Friday, August 30th. The stock was acquired at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the acquisition, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. This trade represents a 2.19 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 21,551 shares of company stock valued at $236,021 over the last 90 days. 30.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

Hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its holdings in Liquidia by 491.2% in the first quarter. California State Teachers Retirement System now owns 46,181 shares of the company's stock worth $681,000 after buying an additional 38,369 shares during the last quarter. Swiss National Bank acquired a new position in Liquidia during the first quarter valued at approximately $1,325,000. Boston Partners acquired a new position in Liquidia during the first quarter valued at approximately $762,000. Marshall Wace LLP acquired a new position in Liquidia during the second quarter valued at approximately $545,000. Finally, Sapient Capital LLC acquired a new position in Liquidia during the third quarter valued at approximately $1,336,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Stock Up 4.2 %

Shares of NASDAQ LQDA traded up $0.43 during midday trading on Friday, hitting $10.58. The company had a trading volume of 620,068 shares, compared to its average volume of 973,889. Liquidia has a twelve month low of $6.69 and a twelve month high of $16.99. The business has a 50-day simple moving average of $10.56 and a two-hundred day simple moving average of $11.41. The firm has a market capitalization of $895.46 million, a price-to-earnings ratio of -6.48 and a beta of 0.21.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).